MICHELLE RENEE GRIFFIN
CIK 1229765 · CFO · last filed 2026-06-29
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$397.7K
Companies
8
Total Filings
57
Lifetime Open-Market Net
-$5.88M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ADPT | Director | 15,625 | $25.45 | $397.7K | -$5.88M | 23 | 2026-06-29 |
| CHINOOK THERAPEUTICS, INC. (KDNY) Delisted | Director | 0 | $40.39 | $0 | $0 | 5 | 2023-08-11 |
| Acer Therapeutics Inc. (ACER) Delisted | Director | — | $0.66 | — | $0 | 5 | 2023-03-16 |
| HTG MOLECULAR DIAGNOSTICS, INC (HTGM) Delisted | Director | 14 | $0.48 | $7 | $0 | 5 | 2022-09-15 |
| Acer Therapeutics Inc. (ACERW) Delisted | Director | — | — | — | $0 | 1 | 2017-10-06 |
| ACHIEVE LIFE SCIENCES, INC. (OGXI) Delisted | CFO | — | — | — | $0 | 5 | 2012-05-10 |
| Trubion Pharmaceuticals, Inc (TRBN) Delisted | Senior V.P. and C.O.O. | 0 | — | — | $0 | 5 | 2010-10-28 |
| ACHIEVE LIFE SCIENCES, INC. (SNUS) Delisted | Director | — | — | — | $0 | 1 | 2007-05-14 |
Recent Filings · Page 2 of 6
57 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-03-06 | ADPT | Mixed | −270 | -$124.4K | EDGAR |
| 2024-03-06 | ADPT | Grant (A) | +31,328 | $0 | EDGAR |
| 2023-08-11 | CHINOOK THERAPEUTICS, INC. (KDNY) Delisted | Disp (D) | −3,300 | $0 | EDGAR |
| 2023-05-31 | CHINOOK THERAPEUTICS, INC. (KDNY) Delisted | Exer (M) | +3,300 | $0 | EDGAR |
| 2023-03-29 | ADPT | Sell (S) | −2,341 | -$19.9K | EDGAR |
| 2023-03-16 | Acer Therapeutics Inc. (ACER) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-03-08 | ADPT | Grant (A) | +14,775 | $0 | EDGAR |
| 2022-09-15 | HTG MOLECULAR DIAGNOSTICS, INC (HTGM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-05-31 | CHINOOK THERAPEUTICS, INC. (KDNY) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-01-28 | ADPT | Grant (A) | +6,689 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.